JBIO — Jade Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology
$21.02
-$0.34 (-1.59%)
Jade Biosciences, Inc. (JBIO) is a biotechnology company listed on NASDAQ. It is led by Tom Frohlich, based in Building 23, Waltham, MA, United States, 02453, with about 55 employees. Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Net income was -$25.2M. JBIO currently screens at market cap $868.2M.
Use this JBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the JBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the JBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Jade Biosciences, Inc. even when a live quote feed is slow.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
JBIO Key Statistics
Market Cap
$868.24M
Volume
200,334
Previous Close
$21.33
Day Range
$21.59 – $22.12
EPS
-$2.44
Revenue
$0.00
Net Income
-$69.63M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
55
JBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$69.63M | -$75.52M | -$51.51M | -$22.96M |
| EPS (Diluted) | -$2.44 | -$2.87 | -$2.10 | -$1.87 |
Total Assets
$80.33M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$33.75M
Operating Cash Flow
-$71.20M
Free Cash Flow
$0.00
Jade Biosciences, Inc. Company Information
- President, CEO & Director
- Tom Frohlich
- Headquarters
- Building 23, Waltham, MA, United States, 02453
- Website
- jadebiosciences.com
- Phone
- 781 312 3013
- IPO / Founded
- 2021-06-30
- Sector
- Healthcare
- Industry
- Biotechnology